Amanta Healthcare LimitedAMANTANSE
This is in reference to the aforementioned intimation filed by M Amanta Healthcare Limited regarding
As filed · Updates
OwnershipImprovingNotablemateriality 66 out of 100
What happened
FactThis is in reference to the aforementioned intimation filed by M/s Amanta Healthcare Limited regarding.
Why it matters
CapitSignal interpretationPromoters buying increases the stake of the people with the most information about the business.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
ContradictedEarlierQ1 FY27
SteriPort Line 3 is expected to have INR90 crores of total capex, out of which almost INR80 crores has been spent so far.
NowQ1 FY27
SVP is expected to have about INR30 crores of capex, out of which about INR7 crores has been spent so far and remaining will be spent in coming quarters.
Change
FactFact conflict
Implication
CapitSignal interpretationThe earlier statement mentions SteriPort Line 3 with a total capex of INR90 crores, while the current statement refers to SVP with a capex of INR30 crores. These cannot both be true for the same project.
Watch next
Fact- Promoter holding before and after
- Looking ahead, we expect the commissioning of our SteriPort expansion by end of current month, followed by SVP (management committed by Q4 FY27)
- On full year basis, annualized basis compared to FY26, our total depreciation will increase by about INR6 cror (management committed by FY27)
Evidence
- Amanta Healthcare Limited has informed the Exchange regarding 'clarification on earlier disclosure submitted on April 1st, 2026, pursuant to SEBI (PIT) Regulations, 2015'.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- PROMOTER_BUYING base 58; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%